SNH Innovation LLP.

SNH Innovation LLP

We are pioneering a new class of cancer immunotherapy to give hope to patients and their family.

we are reimagining medicine

SNH Innovation LLP is pioneering a new class of immunotherapy to give hope to patients and their family with with research and development in this emerging problem.

About Us

SNH Innovation LLP ΄S Goal is to eradicate cancer by developing Nanoparticulate based Antibody Drug Conjugates (NADCs) immunotherapies to fight against cancer. Our approach focuses on Monoclonal antibody based targeting of nanoparticulate of cytotoxic Drug directly to the cancerous cells of tumor and avoid targeting to Normal healthy cells.

We believe in by novel targeting based NADCs therapy increases therapeutic index of cytotoxic payload as compare to conventional dosage forms, By developing novel platform based technology could offer an important opportunity to cancer patient for fighting against cancer.

Our Therapy

Nano Parcticle

Improved Bioavailability. Targeting drug to specific location of Body,High stability,hig carrier capacity and high drug loading

Linker

A stable ADC linker ensures that less cytotoxic payloads fall off before reaching tumor cells, increasing safety and limiting dose

Monoclonal-Antibody

It is designed to bind to antigens that are generally more numerous on the surface of cancer cells than healthy cells

NANOPARTICULATE BASED ADC

ADCs are the increase of the cell killing potential of monoclonal antibodies; the higher tumor selectivity, the increase of drug tolerability and limited systemic exposure

Technologies

We are Developing Life-Changing Therapies Through the Use of Our Proprietary Technologies.

Monoclonal Antibody based Target Therapy comprises Nanoparticulate based Antibody drug conjugates target cancerous cells only, minimize toxic effect associated with marketed conventional Dosage Form. Further Therapeutic Index might be Improved